Overview

* Theravance Q3 revenue slightly beats estimates, driven by Viatris collaboration

* Adjusted net income for Q3 beats estimates, reflecting financial discipline

* YUPELRI net sales in Q3 reach $71.4 mln, up 15% YoY

Outlook

* Theravance expects topline Phase 3 CYPRESS results in Q1 2026

* Company on track to achieve $50 mln TRELEGY sales milestone in 2025

* Theravance expects breakeven non-GAAP net income margin in Q4 2025

Result Drivers

* YUPELRI SALES - Record net sales of $71.4 mln in Q3, up 15% YoY, driven by customer demand and improved net pricing

* STRONG CASH POSITION - Co reports $333 mln in cash and no debt, supporting ongoing and future initiatives

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $19.99 $19.96

Revenue Beat* mln mln (6

Analysts

)

Q3 EPS $0.07

Q3 Beat $2.26 -$6.73

Adjusted mln mln (6

Net Analysts

Income )

Q3 Net $3.62

Income mln

Q3 -$6.46

Operatin mln

g Income

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Theravance Biopharma Inc ( TBPH ) is $20.00, about 26.3% above its November 7 closing price of $14.75

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)